Return to search

Drug discovery platform Atomwise snags $123m Series B

San Francisco-based Atomwise, an AI drug discovery company, has raised $123 million in Series B financing.

San Francisco-based Atomwise, an artificial intelligence-enabled drug discovery company, has raised $123 million in Series B financing. B Capital Group and Sanabil Investments led the round. Originally called Chematria, Atomwise graduated out of University of Toronto’s Techno program in 2012.

Source: Press Release